Stock comparison
Bio-Rad Laboratories
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 72B | RMD |
| Benjamin Graham | 48D | 75B | RMD |
| Philip Fisher | 30F | 75B | RMD |
| Peter Lynch | 10F | 58C | RMD |
| Joel Greenblatt | 42D | 47D | RMD |
| Charlie Munger | 34F | 69B | RMD |
| Terry Smith | 26F | 73B | RMD |
Side-by-side metrics
| Metric | BIO | RMD |
|---|---|---|
| Market cap | $7.78B | $30.18B |
| P/E (TTM) | 39.5x | 19.6x |
| EV/EBIT | 28.0x | 17.1x |
| ROIC (TTM) | 1.95% | 19.63% |
| Gross margin | 51.87% | 61.69% |
| Net margin | 6.52% | 27.44% |
| Revenue CAGR 5y | -3.04% | 12.64% |
| EPS CAGR 5y | -33.51% | 30.73% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
No clear edges - the other side wins or ties on every measured metric.
RMD leads on
- EPS CAGR 5y30.73%vs -33.51%+192%
- Revenue CAGR 5y12.64%vs -3.04%+124%
- Dividend yield1.14%vs 0.0%+100%
- ROIC (TTM)19.63%vs 1.95%+90%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.